Telehealth ADHD prescriptions in New York: the rules through 2026 and what may change

Two layers of law decide whether an ADHD stimulant can be prescribed over video in New York: a federal statute administered by the Drug Enforcement Administration (DEA), and a New York regulation that defers to it. The federal layer is temporary and dated. This article gives the position as of October 13, 2026, the open questions for 2027, and the questions worth putting to a prescriber now.

The position as of October 2026

The federal rule and its extensions

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 set the default: no remote prescribing of a controlled substance without at least one in-person medical evaluation, unless an exception applies. During the COVID-19 public health emergency, the DEA and the Department of Health and Human Services allowed prescribing through telemedicine without that visit.

Those flexibilities have been extended four times: in May 2023, in October 2023, in November 2024 (through December 31, 2025), and on December 31, 2025. The current document, the Fourth Temporary Extension, is effective from January 1, 2026 through December 31, 2026. It covers Schedule II through V medications, which includes ADHD stimulants, and it applies to audio-video encounters. The prescription must still comply with DEA regulations and with applicable federal and state law.

As of October 13, 2026, no fifth extension and no final telemedicine rule had been published in the Federal Register. Unless the DEA acts again, the flexibilities end on December 31, 2026.

What New York adds

New York's own regulation changed on May 21, 2025. Under 10 NYCRR 80.63(d), "No controlled substance shall be prescribed prior to an in-person medical evaluation of the patient by the prescribing practitioner," with listed exceptions.

One exception, 80.63(e)(4), covers prescribing through telemedicine or telehealth, as defined in Article 29-G of the Public Health Law, when it is consistent with state law and with the laws, rules and regulations of the DEA. In plain terms, New York sets no separate in-person requirement of its own for telehealth prescribing. While the DEA flexibilities run, a New York prescriber may start a Schedule II stimulant by audio-video telehealth. If the federal position changes, New York's changes with it.

The same section lists other exceptions: an in-person evaluation by a consulting or referring practitioner within the previous 12 months, a covering practitioner, and an emergency supply of no more than five days for an established patient.

New York also sets no fixed interval for in-person follow-up. The practitioner decides how often to evaluate the patient "utilizing generally accepted medical standards."

What does not change on video

• New York license. Telehealth law does not relax licensing. State Education Department guidance says a practitioner must hold a New York license, or be otherwise authorized, when providing services to a patient located in New York. What counts is where you are physically located during the visit.
• Registry check. The prescriber must consult the Prescription Monitoring Program Registry no more than 24 hours before prescribing, exactly as for an office visit. See I-STOP and the Prescription Monitoring Program.
• Electronic prescription and supply limits. The 30-day and three-month supply rules, the ban on refills and the seven-day rule all apply. They are set out in New York's rules for ADHD stimulant prescriptions.
• A real evaluation. The flexibilities remove a location requirement. They do not shorten what a sound diagnosis involves. See online ADHD diagnosis in New York.

People who cross the Hudson for work or home should know that New Jersey applies different rules to patients who are physically in New Jersey during visits. Since July 8, 2026, New Jersey law requires an in-person visit within 30 days when the first examination for an adult stimulant prescription is by telehealth, and an in-person visit at least once a year. Filling an ADHD prescription across the New York and New Jersey line covers the details.

What may change in 2027

Three things are known, and one is not.

• The proposed special registration rule, published January 17, 2025, described an "Advanced Telemedicine Prescribing Registration" that would let qualified specialized clinicians, with psychiatrists given as an example, prescribe Schedule II through V medications by telemedicine. It was a proposal only.
• The final version of that rule (RIN 1117-AB40) was received by the White House Office of Information and Regulatory Affairs on August 25, 2026 and is listed as pending review.
• The current flexibilities carry an end date of December 31, 2026.
• The text of the final rule is not public. Nobody outside government can say how it treats Schedule II stimulants, whether it will take effect by January 1, 2027, or whether the DEA will extend the flexibilities again.

Any website that tells you what the 2027 rule requires is guessing. Check the Federal Register documents linked under Sources, or ask your prescriber, in December 2026.

One point of federal law is settled and useful. According to the DEA's own explanation in the extension document, once a prescriber has conducted one in-person medical evaluation of a patient, the Ryan Haight limits no longer apply to that prescriber and patient. The prescriber may then prescribe remotely "indefinitely, regardless of how much time has passed since the initial in-person medical evaluation," provided each prescription is for a legitimate medical purpose and complies with other federal and state law. A single in-person visit with your prescriber is therefore a way to remove the federal uncertainty from your own care. Whether that is practical or worthwhile is a matter to raise with the prescriber.

Questions to ask a prescriber now

1. Are you licensed in New York, and will I need to be in New York for every video visit?
2. If the federal telehealth flexibilities end on December 31, 2026, how will you continue my prescriptions?
3. Can you see me in person once, and where, if an in-person evaluation becomes necessary?
4. Are visits by audio and video together? The federal flexibilities for controlled substances refer to audio-video encounters.
5. How often will you want follow-up visits while I am on a stimulant, and can those be by video?
6. If I travel or spend part of the year in another state, can you still treat me?

A telehealth service that cannot answer the second and third questions has not planned for 2027. Warning signs in ADHD clinics and online services lists other checks.

For how one adult ADHD practice handles video and in-person visits, see appointments and telehealth.